 |
| 삼성바이오로직스. (사진=삼성바이오로직스). |
[Alpha Biz= Kim Jisun] Samsung Bioepis announced on Sunday that it has signed a commercialization partnership agreement with Teva Pharmaceutical Industries for the U.S. market introduction of its rare disease treatment, Epysqli (project name SB12, active ingredient eculizumab).
Under the agreement, Samsung Bioepis, as the developer, will be responsible for the production and supply of Epysqli, while Teva will handle marketing and sales activities in the United States.
Epysqli is a biosimilar to Soliris, a rare disease treatment developed by Alexion, now a subsidiary of AstraZeneca after the latter's acquisition of Alexion in 2021. Soliris is a trademark of Alexion.
Samsung Bioepis received approval from the U.S. Food and Drug Administration (FDA) in July of last year for Epysqli to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
